We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 61.50 | 61.00 | 62.00 | 62.00 | 61.50 | 61.50 | 81 | 08:00:13 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 24.48M | -2.7M | -0.0382 | -16.10 | 43.4M |
From Apr 2019 to Apr 2024
TIDMTRX
RNS Number : 2812M
Tissue Regenix Group PLC
12 October 2016
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Unaudited Interim Results for the six months ended 31 July 2016
Leeds, 12(th) October 2016 - Tissue Regenix Group (AIM:TRX) "Tissue Regenix" or "The Group", the regenerative medical devices company, today announces its unaudited interim results for the six months ended 31 July 2016.
Highlights
During the period, the Group has achieved the following important milestones:
-- Delivered revenue of GBP631k (2015: GBP252k) 150% increase -- 510(k) Market clearance for SurgiPure(TM) XD -- First dCELL(R) process approval by the FDA -- OrthoPure(TM) XT regulatory process shortened -- First GPO contract signed in the US for DermaPure(R) -- Further Medicare approvals for DermaPure(R) - 93% now covered -- Appointment of VP Orthopedics North America
Antony Odell, CEO of Tissue Regenix Group plc commented: "Tissue Regenix delivered revenue of GBP631k during the six months to 31(st) July 2016, a 150% increase over the comparative period. Our continued focus on adoption and advocacy was rewarded with further Medicare approvals and our first Group Purchasing Order agreement, both significant steps for the continuing success of DermaPure(R), and highlights the growing commercial traction DermaPure(R) has gained within the competitive US wound care market.
Alongside this, we continue to progress with our European market entry and expect to be in a position to launch our first orthopaedic product, OrthoPure(TM) XT, into this market in H1 2017, with CE mark submission expected to be made a full six months ahead of schedule.
The developing momentum behind our dCELL(R) Technology product portfolio brings us confidence that we will achieve our year end corporate goals. We look forward to reporting our progress in the coming months."
For more information:
Tissue Regenix Group plc Tel: 0330 Caitlin Pearson Corporate Communications 430 3073 Officer ========================================== =========== Jefferies International Ltd Tel: 020 Simon Hardy / Harry Nicholas 7029 8000 ========================================== ===========
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL(R) technology platform.
TISSUE rEGENIX GROUP PLC
INTERIM FINANCIAL REPORT FOR THE SIX MONTHSED 31 JULY 2016
HIGHLIGHTS
"During this period Tissue Regenix Group has made significant progress in operations across both the US and EU, highlighted by a twofold increase in revenue in the US, confirming our ability to successfully commercialise products, whilst also identifying further market entry opportunities."
JOHN SAMUEL
CHAIRMAN
During the period to 31 July 2016 the Group has continued to make significant progress in operations across both the US and EU.
Fundamental to this is the growing adoption of DermaPure(R) in the US Wound Care market, with momentum continuing beyond the initial GBP0.8m reported for the full year, now reflected in a two fold increase in revenue over the previous comparative period.
This, however, should not overshadow the significant strides made in Europe, with OrthoPure(TM) XT now increasingly close to a commercial market launch.
The decision to supersede our initial clinical trial for OrthoPure(TM) XM with a further iteration of the implant should ultimately facilitate its market introduction into Europe, but crucially also assist in the US market launch in the coming years.
Progress in the last six months continues to vindicate our confidence in our product portfolio, both in the marketplace and in the development pipeline.
As the development and expansion of the company continues in line with our ambitions and expectations, we are confident that our results for the full year will reflect this.
OPERATIONAL REVIEW
Overview
In the six months to July 2016 Tissue Regenix Group has continued to see commercial and corporate growth in line with our expectations and strategic goals. DermaPure(R) continues to perform well in the competitive US wound care market, our orthopaedic business is coming to the fore within Europe and significant progress has been made in bringing our dCELL(R) heart valves to the European market.
Alongside these early commercial milestones we continue the development of additional applications arising from our research pipeline agreements with The University of Leeds and research partner the Pontificial Catholic University of Paranà. Furthermore, we continue to exploit opportunities for product line extensions that would allow for a broader use of our existing products.
US
During the period our US business continued to make significant progress, as demonstrated in this set of results, with a two fold increase in sales comparative to the first six months of the previous year. We expect this year to follow a similar revenue profile as seen previously, accelerating towards the end, as demonstrated during H2 FY16 where the revenue increase was +131% against H1.
Further Medicare coverage has been gained, with now only one jurisdiction outstanding. Our focus on adoption and advocacy continues as the importance of health economics increases within the US healthcare market, and the economic advantages of products such as DermaPure(R) become apparent.
As we look to meet the demand of new applications for DermaPure(R) we have expanded our portfolio of products to allow for larger and thicker sizes in response to physician feedback. We continue to pursue opportunities in different markets such as dentistry and burns and anticipate further progress in this regard in the coming year.
The 510(k) market clearance for SurgiPure(TM) XD was another major inflection point. This is the first time the FDA has reviewed the full dCELL(R) process and SurgiPure(TM) XD therefore becomes our first FDA approved product, with an expected launch in H217.
Alongside this we have also progressed with the groundwork for our US Orthopedic subsidiary, appointing a VP for North America. With an initial focus on human tissue applications, we have begun discussions with multiple potential partners. In conjunction with these developments, we have established a clinical advisory board consisting of five experts with varying specialties in sports medicine, with an emphasis on ligament reconstruction, meniscal replacement, and cartilage restoration. We expect this area of our business to develop significantly over the coming year.
Europe
Orthopaedics continues to be our primary focus within the European market and our recent announcement, that the CE mark submission for OrthoPure(TM) XT (porcine tendon) would be completed six months ahead of schedule is a testament to the hard work ongoing in our orthopaedic division, whilst also highlighting the growing need and demand for such a treatment within this field. We anticipate that we will be in a position to launch OrthoPure(TM) XT into the European market in H117.
The OrthoPure(TM) XM (porcine meniscus) clinical trial closed earlier in the year, with the clinical data showing biocompatibility and integration into the patient's tissues. Feedback from the trial led to the decision to undertake a second clinical trial with a modified implant to allow the same product to be marketed in both the EU and US.
GBM-V, our Joint Venture tissue bank in Rostock, Germany, continues to carve out a path for our human tissue applications in mainland Europe, with an initial focus on CardioPure(TM), dCELL(R) heart valves, and DermaPure(R). We now have an experienced team in place to lead us through the regulatory process and currently remain on track to produce the first heart valves in H217.
Summary and Outlook
The next twelve months promise some significant milestones for Tissue Regenix, including the launch of our first orthopaedic application in Europe, the launch of our second wound care product, SurgiPure(TM) XD into the US and the ongoing regulatory submissions to the German authorities for decellurised tissues to be treated at GBM-V. Alongside this, the continued growth of DermaPure(R), as evidenced by these results, and the ongoing development of our orthopaedic business within the US ensure that we remain on track to end our year accomplishing our corporate goals, and we look forward to reporting our progress over the coming months.
Financial Summary
For the 6 months ended 31 July 2016 Tissue Regenix Group delivered revenue of GBP631k (2015: GBP252k) generating an operating loss of GBP5,523k (2015: GBP4,133k). With finance income of GBP81k (2015: GBP116k) and a research and development tax credit of GBP280k (2015: GBP335k) the loss after tax was GBP5,162k (2015: GBP3,682k), of which GBP5,082k (2015: GBP3,682k) was attributable to the equity holders of the parent company. Cash balances at the end of the period were GBP13,515k (2015: GBP24,887k) and the Group was debt free. The results were in line with our expectations.
Wound Care
Wound care revenue for the period of GBP631k (2015: GBP244k) was derived from sales of DermaPure(R) in the USA, representing a more than two fold increase over the prior period. The local currency equivalents, to eliminate the effects of exchange, were $891k (2015: $371k). As was the case in the previous year, revenue phasing across the year is expected to be weighted towards H2. With more visibility now regarding the appointment of distributors and contract approvals, the 12-month revenue guidance range has been narrowed to $2.5m -$3.5m compared to the 12-month prior period of $1.2m (however, please note shortened accounting period below). Gross margin for the period for the Wound Care division was 81% (2015: 75%). SG&A costs increased as expected, impacted by the full year effect of previous year direct sales hires and commission costs, which increase with revenue.
The commission costs were $290k (2015: $100k), which as a percentage of sales was therefore 32.5% (2015: 27.0%). Guidance for full year margin and commission percentage remain at c.80% and c.37.5% respectively.
Orthopaedics
The costs incurred of GBP1,300k (2015: GBP1,050k) consisted primarily of clinical trial costs as both OrthoPure(TM) XM and OrthoPure(TM) XT moved through the human trial phase. The costs were in line with our expectations and previous guidance. We expect to see the first revenue from this division in H117 following commercialisation of OrthoPure(TM) XT.
Cardiac
The results for this segment are not material during this period. However, the joint venture, GBM-V, set up earlier in the year remains on track to launch CardioPure(TM) heart valves in Germany during 2017.
Central
Operation costs are mainly incurred centrally and are in general not allocated to individual operating units. Costs remained flat over the period at GBP1,406k (2015: GBP1,417k).
Accounting reference date change
As noted previously the Group has changed its accounting reference date to 31 December. The next reporting period will therefore be for the 11 months to 31 December 2016.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)
For the six months to 31 July 2016
Hot Features
Premium
6 months 6 months 12 months
to to to
31 July 2016 31 July 2015 31 Jan 2016
Notes GBP'000 GBP'000 GBP'000
--------------------------------------------------- ----- ------------- ------------- ------------
Revenue 631 252 816
Cost of sales (119) (62) (154)
--------------------------------------------------- ----- ------------- ------------- ------------
Gross profit 512 190 662
Administrative expenses (6,035) (4,323) (10,904)
--------------------------------------------------- ----- ------------- ------------- ------------
Operating loss (5,523) (4,133) (10,242)
Finance income 81 116 213
--------------------------------------------------- ----- ------------- ------------- ------------
Loss before tax (5,442) (4,017) (10,029)
Taxation 4 280 335 527
--------------------------------------------------- ----- ------------- ------------- ------------
Loss after tax (5,162) (3,682) (9,502)
--------------------------------------------------- ----- ------------- ------------- ------------
Attributable to:
Equity holders of the parent (5,082) (3,682) (9,410)
Non-controlling (80) - (92)
--------------------------------------------------- ----- ------------- ------------- ------------
(5,162) (3,682) (9,502)
--------------------------------------------------- ----- ------------- ------------- ------------
Other comprehensive income/(expense):
Foreign currency translation differences - foreign
operations (38) 4 (1)
--------------------------------------------------- ----- ------------- ------------- ------------
TOTAL COMPREHENSIVE EXPENSE FOR THE YEAR (5,200) (3,678) (9,503)
--------------------------------------------------- ----- ------------- ------------- ------------
Attributable to:
Equity holders of the parent (5,105) (3,678) (9,411)
Non-controlling interests (95) - (92)
--------------------------------------------------- ----- ------------- ------------- ------------
(5,200) (3,678) (9,503)
--------------------------------------------------- ----- ------------- ------------- ------------
Loss per share
Basic and diluted on loss attributable to equity
holders of the parent 5 (0.68)p (0.50)p (1.27)p
--------------------------------------------------- ----- ------------- ------------- ------------
The loss for the period arises from the Group's continuing operations.
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
For the six months to 31 July 2016
Attributable to equity holders
of parent
Reserve Share
Reverse for based Retained
Share Share Merger acquisition own payment earnings Non-controlling Total
capital premium reserve reserve shares reserve deficit Total interests equity
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
---------------- ------- ------- ------- ----------- ------- ------- -------- ------- --------------- -------
At 31 January
2015 3,271 31,972 10,884 (7,148) (831) 810 (27,380) 11,578 - 11,578
---------------- ------- ------- ------- ----------- ------- ------- -------- ------- --------------- -------
Loss for the
period - - - - - - (3,682) (3,682) - (3,682)
Other
comprehensive
expense - - - - - - 4 4 - 4
---------------- ------- ------- ------- ----------- ------- ------- -------- ------- --------------- -------
Loss and total
comprehensive
expense for the
year - - - - - - (3,678) (3,678) - (3,678)
Issue of shares 526 18,422 - - - - - 18,948 - 18,948
Exercise of
share options 1 23 - - - - - 24 - 24
Share based
payment expense - - - - - 90 - 90 - 90
---------------- ------- ------- ------- ----------- ------- ------- -------- ------- --------------- -------
At 31 July 2015 3,798 50,417 10,884 (7,148) (831) 900 (31,058) 26,962 - 26,962
---------------- ------- ------- ------- ----------- ------- ------- -------- ------- --------------- -------
Loss and total
comprehensive
expense for the
year - - - - - - (5,733) (5,733) (92) (5,825)
Non-controlling
interest
arising on
creation of
a joint venture - - - - - - - - 9 9
Exercise of
share options 3 44 - - - - - 47 - 47
Share based
payment expense - - - - - 46 - 46 - 46
---------------- ------- ------- ------- ----------- ------- ------- -------- ------- --------------- -------
At 31 January
2016 3,801 50,461 10,884 (7,148) (831) 946 (36,791) 21,322 (83) 21,239
---------------- ------- ------- ------- ----------- ------- ------- -------- ------- --------------- -------
Loss for the
period - - - - - - (5,082) (5,082) (80) (5,162)
Other
comprehensive
expense - - - - - - (23) (23) (15) (38)
---------------- ------- ------- ------- ----------- ------- ------- -------- ------- --------------- -------
Loss and total
comprehensive
expense for the
period - - - - - - (5,105) (5,105) (95) (5,200)
Share based
payment expense - - - - - 135 - 135 - 135 ---------------- ------- ------- ------- ----------- ------- ------- -------- ------- --------------- ------- At 31 July 2016 3,801 50,461 10,884 (7,148) (831) 1,081 (41,896) 16,352 (178) 16,174 ---------------- ------- ------- ------- ----------- ------- ------- -------- ------- --------------- -------
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED)
As at 31 July 2016
31 July 2016 31 July 2015 31 Jan 2016
Notes GBP'000 GBP'000 GBP'000
------------------------------------------------ ----- -------------- -------------- -------------
Non-current assets
Property, plant and equipment 1,075 878 901
------------------------------------------------ ----- -------------- -------------- -------------
Total non-current assets 1,075 878 901
------------------------------------------------ ----- -------------- -------------- -------------
Current assets
Inventory 128 17 64
Trade and other receivables 2,586 1,801 2,325
Cash and cash equivalent 13,515 24,887 19,907
------------------------------------------------ ----- -------------- -------------- -------------
Total current assets 16,229 26,705 22,296
------------------------------------------------ ----- -------------- -------------- -------------
Total assets 17,304 27,583 23,197
------------------------------------------------ ----- -------------- -------------- -------------
Current liabilities
Trade and other payables (1,130) (621) (1,958)
------------------------------------------------ ----- -------------- -------------- -------------
Total liabilities (1,130) (621) (1,958)
------------------------------------------------ ----- -------------- -------------- -------------
Net assets 16,174 26,962 21,239
------------------------------------------------ ----- -------------- -------------- -------------
Equity
Share capital 6 3,801 3,798 3,801
Share premium 6 50,461 50,417 50,461
Merger reserve 6 10,884 10,884 10,884
Reverse acquisition reserve 6 (7,148) (7,148) (7,148)
Reserve for own shares (831) (831) (831)
Share based payment reserve 1,081 900 946
Retained earnings deficit 7 (41,896) (31,058) (36,791)
------------------------------------------------ ----- -------------- -------------- -------------
Equity attributable to equity holders of parent 16,352 26,962 21,322
Non-controlling interests (178) - (83)
------------------------------------------------ ----- -------------- -------------- -------------
Total equity 16,174 26,962 21,239
------------------------------------------------ ----- -------------- -------------- -------------
Approved by the Board and authorised for issue on 12 October 2016
John Samuel
Chairman
Ian Jefferson
Chief Financial Officer
CONDENSED CONSOLIDATED CASH FLOW STATEMENT (UNAUDITED)
For the six months ended 31 July 2016
6 months 6 months 12 months
to to to
31 July 2016 31 July 2015 31 Jan 2016
GBP'000 GBP'000 GBP'000
------------------------------------------------- ------------- ------------- ------------
Operating Activities
Operating loss (5,523) (4,133) (10,242)
Adjustment for non-cash items:
Depreciation of property, plant & equipment 158 118 245
Share based payment 135 90 136
Tax refunded - 745 745
------------------------------------------------- ------------- ------------- ------------
Operating cash outflow (5,230) (3,180) (9,116)
------------------------------------------------- ------------- ------------- ------------
(Increase)/decrease in inventory (64) 17 (30)
Decrease/(increase) in trade & other receivables 19 (264) (596)
(Decrease)/increase in trade & other payables (866) (470) 862
------------------------------------------------- ------------- ------------- ------------
Net cash outflow from operations (6,141) (3,897) (8,880)
------------------------------------------------- ------------- ------------- ------------
Investing activities
Interest received 81 116 213
Net cash acquired on creation of joint venture - - 9
Purchase of property, plant & equipment (332) (561) (711)
------------------------------------------------- ------------- ------------- ------------
Net cash outflow from investing activities (251) (445) (489)
------------------------------------------------- ------------- ------------- ------------
Financing activities
Proceeds from issue of share capital - 18,972 19,019
------------------------------------------------- ------------- ------------- ------------
Net cash inflow from financing activities - 18,972 19,019
------------------------------------------------- ------------- ------------- ------------
(Decrease)/increase in cash and cash equivalents (6,392) 14,630 9,650
Cash and cash equivalents at start of period 19,907 10,257 10,257
------------------------------------------------- ------------- ------------- ------------
Cash and cash equivalents at end of period 13,515 24,887 19,907
------------------------------------------------- ------------- ------------- ------------
NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)
For the six months ended 31 July 2016
1) Basis of preparation
The interim financial information set out in this statement for the six months ended 31 July 2016 and the comparative figures for the six months ended 31 July 2015 are unaudited. This information does not constitute statutory accounts as defined in Section 435 of the Companies Act 2006.
The comparative figures for the financial year ended 31 January 2016 are not the Company's statutory accounts for that financial year. Those accounts have been reported on by the Company's auditors and delivered to the Registrar of Companies. The report of the auditor was (i) unqualified, (ii) did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying their report, and (iii) did not contain a statement under section 498 (2) or (3) of the Companies Act 2006.
This interim statement, which is neither audited nor reviewed, has been prepared in accordance with the measurement and recognition criteria of Adopted IFRSs. It does not include all the information required for the full annual financial statements, and should be read in conjunction with the financial statements of the Group as at and for the year ended 31 January 2016. It does not comply with IAS 34 "Interim Financial Reporting" as is permissible under the rules of the AIM Market ("AIM").
The financial information has been prepared on a going concern basis and is presented in sterling to the nearest GBP'000.
The preparation of financial information in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management's best knowledge of the amount, event or actions, actual events ultimately may differ from those estimates.
The interim financial information does not include all financial risk management information and disclosures required in annual financial statements. There have been no significant changes in any risk or risk management policies since 31 January 2016. The principal risks and uncertainties are largely unchanged and are as disclosed in the Annual Report for the year ended 31 January 2016.
The accounting policies applied in preparing these interim financial statements are the same as those applied in the preparation of the annual financial statements for the year ended 31 January 2016, as described in those financial statements other than standards, amendments and interpretations which became effective after 1 February 2016 and were adopted by the Group. These have had no significant impact on the Group's profit for the period or equity. The Board approved these interim financial statements on 12 October 2016.
2) Significant accounting policies
The condensed consolidated financial statements have been prepared under the historical cost convention in accordance with International Financial Reporting Standards as adopted by the European Union.
The accounting policies adopted are consistent with those followed in the preparation of the audited financial statements of Tissue Regenix Group Plc for the year ended 31 January 2016 and are disclosed in those statements.
3) Segmental reporting
Operating segments
The Group is organised into Cardiac, Wound Care and Orthopaedics divisions for internal management, reporting and decision-making, based on the nature of the products of the Group's businesses. Managers have been appointed within these divisions, who report to the board. These are the reportable operating segments in accordance with IFRS8 "Operating Segments". The Directors recognise that the operations of the Group are dynamic and therefore this position will be monitored as the Group develops. In accordance with IFRS8, the Group has derived the information for its operating segments using the information used by the Chief Operating Decision Maker. The Group has identified the Board of Directors as the Chief Operating Decision Maker as it is responsible for the allocation of resources to the operating segments and assessing their performance.
Central overheads, which primarily relate to operations of the Group function, are not allocated to the business units.
Wound Care Cardiac Central Total
6 months Orthopaedics 6 months 6 months 6 months
to 6 months to to to to
31 July 31 July 31 July 31 July 31 July
2016 2015 2016 2015 2016 2015 2016 2015 2016 2015
GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000 GBP000
--------------------- ------- -------- ------- ------- ------- ------- ------- -------- ------- --------
Revenue 631 244 - - - - - 8 631 252
Cost of sales (119) (62) - - - - - - (119) (62)
--------------------- ------- -------- ------- ------- ------- ------- ------- -------- ------- --------
Gross Profit 512 182 - - - - - 8 512 190
SG&A (3,074) (1,749) (1,300) (1,050) (255) (107) (1,406) (1,417) (6,035) (4,323)
--------------------- ------- -------- ------- ------- ------- ------- ------- -------- ------- --------
Operating loss (2,562) (1,567) (1,300) (1,050) (255) (107) (1,406) (1,409) (5,523) (4,133)
Finance income - - - - - - 81 116 81 116
--------------------- ------- -------- ------- ------- ------- ------- ------- -------- ------- --------
Loss before taxation (2,562) (1,567) (1,300) (1,050) (255) (107) (1,325) (1,293) (5,442) (4,017)
Taxation 50 54 200 256 30 7 - 18 280 335
--------------------- ------- -------- ------- ------- ------- ------- ------- -------- ------- --------
Loss for the year (2,512) (1,513) (1,100) (794) (225) (100) (1,325) (1,275) (5,162) (3,682)
--------------------- ------- -------- ------- ------- ------- ------- ------- -------- ------- --------
Wound Care Orthopaedics Cardiac Central Total
12 months 12 months 12 months 12 months 12 months
to to to to to
31 Jan 31 Jan 31 Jan 31 Jan 31 Jan
2016 2016 2016 2016 2016
GBP000 GBP000 GBP000 GBP000 GBP000
--------------------- ---------- ------------ ---------- ---------- ----------
Revenue 808 - - 8 816
Cost of sales (154) - - - (154)
--------------------- ---------- ------------ ---------- ---------- ----------
Gross Profit 654 - - 8 662
SG&A (4,938) (2,382) (352) (3,232) (10,904)
--------------------- ---------- ------------ ---------- ---------- ----------
Operating loss (4,284) (2,382) (352) (3,224) (10,242)
Finance income - - - 213 213
--------------------- ---------- ------------ ---------- ---------- ----------
Loss before taxation (4,284) (2,382) (352) (3,011) (10,029)
Taxation 169 324 16 18 527
--------------------- ---------- ------------ ---------- ---------- ----------
Loss for the year (4,115) (2,058) (336) (2,993) (9,502)
--------------------- ---------- ------------ ---------- ---------- ----------
The following table provides disclosure of the Group's revenue by geographical market based on location of the customer:
6 months 6 months 12 months
to to to
31 July 2016 31 July 2015 31 Jan 2016
GBP'000 GBP'000 GBP'000
-------------- ------------- ------------- ------------
USA 631 244 808
Rest of world - 8 8
-------------- ------------- ------------- ------------
631 252 816
-------------- ------------- ------------- ------------
4) Taxation
6 months 6 months 12 months
to to to
31 July 2016 31 July 2015 31 Jan 2016
GBP'000 GBP'000 GBP'000
----------------------------------------------------------- ------------- ------------- ------------
Current tax:
Tax credit on research and development costs in the period 280 335 527
----------------------------------------------------------- ------------- ------------- ------------
280 335 527
Deferred tax:
Origination and reversal of temporary timing differences - - -
----------------------------------------------------------- ------------- ------------- ------------
Tax credit on loss on ordinary activities 280 335 527
----------------------------------------------------------- ------------- ------------- ------------
The Group has accumulated losses available to carry forward against future trading profits. No deferred tax asset has been recognised in respect of tax losses.
5) Loss per share (basic and diluted)
Basic loss per share is calculated by dividing the loss attributable to equity holders of the parent by the weighted average number of ordinary shares in issue during the period excluding own shares held jointly by the Tissue Regenix Employee Share Trust and certain employees. Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares in issue during the period to assume conversion of all dilutive potential ordinary shares.
6 months 6 months 12 months
to to to
31 July 2016 31 July 2015 31 Jan 2016
GBP'000 GBP'000 GBP'000
------------------------------------------------------------ ------------- ------------- ------------
Total loss attributable to the equity holders of the parent (5,082) (3,682) (9,410)
------------------------------------------------------------ ------------- ------------- ------------
No. No. No.
------------------------------------------------------------ ------------- ------------- ------------
Weighted average number of ordinary shares in issue during
the period 743,183,878 737,434,237 739,919,809
------------------------------------------------------------ ------------- ------------- ------------
Loss per share Basic and diluted on loss for the period (0.68)p (0.50)p (1.27)p ------------------------------------------------------------ ------------- ------------- ------------
The Company has issued employees options over 29,376,332 ordinary shares and there are 16,940,386 jointly owned shares which are potentially dilutive. There is, however, no dilutive effect of these issued options as there is a loss for each of the periods concerned.
6) Share capital
Share Reverse acquisition
capital Share premium Merger reserve reserve Total
Number GBP000 GBP000 GBP000 GBP000 GBP000
---------------------------------- ----------- -------- ------------- -------------- ------------------- -------
Total Ordinary shares of 0.5p each
as at 31 January 2015 654,123,031 3,271 31,972 10,884 (7,148) 38,979
Issued for cash 105,263,158 526 18,422 - - 18,948
Issued on exercise of share
options 266,904 1 23 - - 24
---------------------------------- ----------- -------- ------------- -------------- ------------------- -------
Total Ordinary shares of 0.5p each
as at 31 July 2015 759,653,093 3,798 50,417 10,884 (7,148) 57,951
Issued on exercise of share
options 471,171 3 44 - - 47
---------------------------------- ----------- -------- ------------- -------------- ------------------- -------
Total Ordinary shares of 0.5p each
as at 31 January 2016 760,124,264 3,801 50,461 10,884 (7,148) 57,998
Issued for cash
Issued on exercise of share - - - - - -
options
---------------------------------- ----------- -------- ------------- -------------- ------------------- -------
Total Ordinary shares of 0.5p each
as at 31 July 2016 760,124,264 3,801 50,461 10,884 (7,148) 57,998
---------------------------------- ----------- -------- ------------- -------------- ------------------- -------
7) Movement in retained earnings and reserve for own shares
Retained Reserve
earnings for own
deficit shares
GBP000 GBP000
-------------------- --------- --------
At 31 January 2015 (27,380) (831)
-------------------- --------- --------
Loss for the period (3,682) -
Exchange movement 4 -
-------------------- --------- --------
At 31 July 2015 (31,058) (831)
-------------------- --------- --------
Loss for the period (5,728) -
Exchange movement (5) -
-------------------- --------- --------
At 31 January 2016 (36,791) (831)
Loss for the period (5,082) -
Exchange movement (23) -
-------------------- --------- --------
At 31 July 2016 (41,896) (831)
-------------------- --------- --------
8. Interim financial report
A copy of this interim report will be distributed to shareholders and is also available on the Company's website at www.tissueregenix.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IR KFLFFQBFZFBZ
(END) Dow Jones Newswires
October 12, 2016 02:00 ET (06:00 GMT)
1 Year Tissue Regenix Chart |
1 Month Tissue Regenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
